Radiotherapy and immunology

The majority of cancer patients receive radiotherapy. Wang et al. review preclinical and clinical data related to the importance of immune responses to radiotherapy-induced anti-tumor effects, as well as blockade of immune checkpoints PD-1/PD-L1 and/or CTLA-4 in combination with radiotherapy.

• Publication year

  2024

• Venue

  Journal of Experimental Medicine

• Publication date

  2024-05-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1084/jem.20232101PMID 38771260PMCID 11110906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis

  2024cited by this paper
• Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

  2024cited by this paper
• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

  2024cited by this paper
• A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

  2023cited by this paper
• STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy

  2023cited by this paper
• Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways

  2023influential reference
• Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.

  2023cited by this paper
• YTHDF2 inhibition potentiates radiotherapy anti-tumor efficacy

  2023influential reference
• How chemokines organize the tumour microenvironment

  2023cited by this paper
• ALKBH5/YTHDF2‐mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation

  2023cited by this paper
• Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial.

  2023cited by this paper
• Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

  2023cited by this paper
• Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.

  2023cited by this paper
• Macrophages at the interface of the co-evolving cancer ecosystem.

  2023cited by this paper
• Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches

  2023cited by this paper
• Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  2023cited by this paper
• The roles and implications of RNA m6A modification in cancer

  2023cited by this paper
• A Three‐in‐One Nanoscale Coordination Polymer for Potent Chemo‐Immunotherapy

  2023cited by this paper
• Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma

  2023cited by this paper
• A timeline of tumour-associated macrophage biology

  2023cited by this paper
• Cancer cell-specific cGAS/STING Signaling pathway in the era of advancing cancer cell biology.

  2023cited by this paper
• Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.

  2023cited by this paper
• RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy.

  2023cited by this paper
• Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

  2023cited by this paper
• Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

  2023cited by this paper
• Myeloid-Derived Suppressor Cells and Radiotherapy.

  2022cited by this paper
• Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

  2022cited by this paper
• Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges

  2022cited by this paper
• Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

  2022cited by this paper
• Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration

  2022cited by this paper
• Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

  2022cited by this paper
• Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.

  2022cited by this paper
• Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

  2022cited by this paper
• Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy

  2022cited by this paper
• Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors

  2022cited by this paper
• Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity

  2022cited by this paper
• Current landscape and future directions of bispecific antibodies in cancer immunotherapy

  2022cited by this paper
• LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

  2022cited by this paper
• TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

  2022cited by this paper
• Macrophage diversity in cancer revisited in the era of single-cell omics.

  2022cited by this paper
• A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

  2022cited by this paper
• Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).

  2022cited by this paper
• DCs at the center of help: Origins and evolution of the three-cell-type hypothesis

  2022cited by this paper
• Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling

  2022cited by this paper
• FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

  2022cited by this paper
• Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer.

  2022cited by this paper
• Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

  2022cited by this paper
• The paradox of radiation and T cells in tumors

  2022cited by this paper
• Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma

  2022cited by this paper
• Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004

  2022cited by this paper
• Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

  2022cited by this paper
• Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

  2022cited by this paper
• Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review

  2022cited by this paper
• Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

  2022cited by this paper
• Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

  2022cited by this paper
• The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia

  2021cited by this paper
• m6A RNA methylation: from mechanisms to therapeutic potential

  2021cited by this paper
• Radiotherapy and immunotherapy: open questions and future strategies.

  2021cited by this paper
• All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages

  2021cited by this paper
• STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

  2021cited by this paper
• Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.

  2021cited by this paper
• Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

  2021cited by this paper
• METTL14 facilitates global genome repair and suppresses skin tumorigenesis

  2021cited by this paper
• Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

  2021cited by this paper
• Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control.

  2021cited by this paper
• S100A9 Activates the Immunosuppressive Switch Through the PI3K/Akt Pathway to Maintain the Immune Suppression Function of Testicular Macrophages

  2021cited by this paper
• Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

  2021cited by this paper
• Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.

  2021cited by this paper
• Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

  2021cited by this paper
• Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy

  2021cited by this paper
• From purines to purinergic signalling: molecular functions and human diseases

  2021cited by this paper
• Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer.

  2021cited by this paper
• Next-generation cytokines for cancer immunotherapy

  2021cited by this paper
• Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

  2021cited by this paper
• TGF-beta signaling in cancer radiotherapy.

  2021cited by this paper
• A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

  2021cited by this paper
• A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes

  2021cited by this paper
• Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

  2021influential reference
• Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy.

  2021cited by this paper
• N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway

  2021cited by this paper
• Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

  2021cited by this paper
• A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).

  2021cited by this paper
• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

  2021cited by this paper
• Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

  2021cited by this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021influential reference
• METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation.

  2020cited by this paper
• The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells

  2020cited by this paper
• TGF-β in radiotherapy: mechanisms of tumor resistance and normal tissues injury.

  2020cited by this paper
• Inflammatory microenvironment remodelling by tumour cells after radiotherapy

  2020cited by this paper
• m6A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis

  2020cited by this paper
• The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

  2020cited by this paper
• DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity

  2020cited by this paper
• Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

  2020cited by this paper
• Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

  2020cited by this paper
• Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

  2020cited by this paper
• Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

  2020cited by this paper
• RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

  2020cited by this paper
• Carcinoma

  2020cited by this paper
• Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer

  2020cited by this paper
• Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

  2020cited by this paper

• In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy

  2026cites this paper
• Single-fraction radiotherapy with a bioactive depot of CD39 blockade eradicates malignant tumor.

  2026cites this paper
• Irradiated Tumor Cell-Derived Microparticles Activate Systemic Anti-Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils.

  2026cites this paper
• Integrating single-cell and bulk transcriptomes identifies B cell features associated with neoadjuvant chemoradiotherapy sensitivity in rectal cancer

  2026cites this paper
• Nanosensitizer for enhanced radiotherapy via tumor microenvironment reshaping and ROS amplification

  2026cites this paper
• Recapitulating the tumour microenvironment: advancing personalised radiation therapy through organoid technology.

  2026cites this paper
• MSA-2 Loaded Three-Dimensional Metal Covalent Organic Framework for Synergistic Radiosensitization and Innate Immune Activation.

  2026cites this paper
• Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies.

  2026cites this paper
• Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.

  2026cites this paper
• Inducing Ferroptosis: Sensitization Strategy for Radiotherapy and Its Application.

  2026cites this paper
• The application of MOF-based drug delivery systems in tumor immunotherapy.

  2026cites this paper
• Platinum-based functional nanomaterials: mechanisms and therapeutic strategies in cancer radiotherapy sensitization

  2026cites this paper
• Evaluating deep learning-based image segmentation for radiotherapy planning in pelvic and abdominal cancers

  2026cites this paper
• Temporal dynamics of lymphocytes in prostate cancer patients treated with proton therapy

  2025cites this paper
• Targeting DNA Damage Repair to Enhance Antitumor Immunity in Radiotherapy: Mechanisms and Opportunities

  2025cites this paper
• A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.

  2025cites this paper
• Cholesterol biosynthesis induced by radiotherapy inhibits cGAS–STING activation and contributes to colorectal cancer treatment resistance

  2025cites this paper
• Berberine in the treatment of radiation-induced skin injury: insights from proteomics and network pharmacology

  2025cites this paper
• Radiotherapeutic enhancement using ultrasound-stimulated microbubbles: a critical review

  2025cites this paper
• YTHDFs as radiotherapy checkpoints in tumor immunity.

  2025cites this paper
• Unveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk

  2025cites this paper
• Potential value and cardiovascular risks of programmed cell death in cancer treatment

  2025cites this paper
• Interplay between AHR genotypes, lifestyle factors and adjuvant breast cancer treatments significantly impacts clinical outcome in a population-based cohort

  2025cites this paper
• The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy

  2025cites this paper
• Mitophagy: A key regulator of radiotherapy resistance in the tumor immune microenvironment.

  2025cites this paper
• Prognostic Differences of Adjuvant Radiotherapy in Breast Cancer Cohorts Based on PRLR Genotypes, Expression, and Transcriptional Network Regulation

  2025cites this paper
• Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation

  2025cites this paper
• Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair

  2025cites this paper
• Prospects and Challenges of Lung Cancer Vaccines

  2025cites this paper
• Preconditioning with Low-Dose Radiation Improves Antitumor Immunity and Survival in DC-Vaccinated Mice

  2025cites this paper
• A New Biomarker for Predicting the Abscopal Effect: Quantifying Polyclonal Effector Tumor Antigen-Specific T Cells by Using Nanoparticles Loading Whole Tumor Antigens.

  2025cites this paper
• The impact of tumor microenvironment and treatment schedule on the effectiveness of radiation therapy

  2025cites this paper
• Inhibition of DDR1 potentiates carbon ion radiotherapy by promoting ferroptosis and immunogenic death in head and neck squamous cell carcinoma

  2025cites this paper
• Circumventing tumor immune evasion: Coordinated immunotherapy via in situ tumor nanovaccines and local ablation

  2025cites this paper
• Overview of Yttrium-90 radioembolization for advanced hepatocellular carcinoma: Current status and future perspectives

  2025cites this paper
• Novel drug-free cascaded nanoparticles induce tumor-specific ROS storms via multimodal synergistic anticancer therapy

  2025cites this paper
• Herbal based nanoparticles as a possible and potential treatment of cancer: a review

  2025cites this paper
• Maintaining cardiac homeostasis by translational selenium nanoparticles with rapid selenoproteins regulation to achieve radiation-induced heart prevention

  2025cites this paper
• Extracellular vesicles in tumor immunity: mechanisms and novel insights

  2025cites this paper
• Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33.

  2025cites this paper
• Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma

  2025cites this paper
• Interactions Between Radiotherapy Resistance Mechanisms and the Tumor Microenvironment.

  2025cites this paper
• Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?

  2025cites this paper
• A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.

  2025cites this paper
• A customizable 32P hydrogel applicator for brachytherapy of skin hemangioma based on machine learning and 3D-printing.

  2025cites this paper
• Extracellular vesicles as the common denominator among the 7 Rs of radiobiology: From the cellular level to clinical practice.

  2025cites this paper
• Reengineering the Tumor Oxygen Microenvironment in Radiotherapy to Enhance T‐Cell Function for Radio‐Immunotherapy

  2025cites this paper
• Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

  2025cites this paper
• Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy

  2025cites this paper
• Facts and hopes in radioimmunotherapy for localized stages of cancer.

  2025cites this paper
• Inflammation accelerates metastasis: Medulloblastoma leptomeningeal dissemination.

  2025cites this paper
• Marker-Less Lung Tumor Tracking from Real-Time Color X-Ray Fluoroscopic Images Using Cross-Patient Deep Learning Model

  2025cites this paper
• Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.

  2025cites this paper
• Regulatory T cells in liver metastases: emerging and divergent roles in tumour progression

  2025cites this paper
• Radiation Without Borders: Unraveling Bystander and Non-Targeted Effects in Oncology

  2025cites this paper
• Successful sequential chemo-immunotherapy and reduced-volume brachytherapy for bulky residual cervical tumor after external beam radiotherapy: two case reports

  2025cites this paper
• Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer

  2025cites this paper
• Liver X receptor: A potential target for inflammatory bowel disease and colorectal cancer (Review)

  2025cites this paper
• A Radiotherapy‐Responsive Peptide Hydrogel for Pulsatile Release of mRNA‐LNPs Synergizes with Immune Activation to Prevent Breast Cancer Recurrence

  2025cites this paper
• Synergistic anticancer effects of Dracaena cinnabari and Aloe perryi extracts on colorectal cancer cells: A flow cytometry analysis of toxicity, cell cycle, apoptosis, and autophagy

  2025cites this paper
• Application of radiotherapy-preexcited gambogic acid dual targeting nanoparticles in colorectal cancer

  2025cites this paper
• Radiation-Induced Immune Responses from the Tumor Microenvironment to Systemic Immunity

  2025cites this paper
• The role of hyperthermia in modern radiation treatment- state of art

  2025cites this paper
• Targeting gut microbiota and metabolites in cancer radiotherapy

  2025cites this paper
• MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors

  2024cites this paper
• Comprehensive analysis of the potential biological significance of CCL5 in pan-cancer prognosis and immunotherapy

  2024cites this paper
• Combination of radiotherapy and PD-L1 blockade induces abscopal responses in EGFR-mutated lung cancer through activating CD8+ T cells

  2024cites this paper
• Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.

  2024cites this paper
• A novel high‐risk model identified by epithelial–mesenchymal transition predicts prognosis and radioresistance in rectal cancer

  2024cites this paper
• Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors.

  2024cites this paper
• N6-methyladenosine reader YTHDF2 in cell state transition and antitumor immunity

  2024cites this paper
• Injectable polydopamine/curcumin dual-modified polylactic acid/polycaprolactone coaxial staple fibers for chronotropic treatment of oral squamous cell carcinoma.

  2024cites this paper
• Advances in nanoparticle-based radiotherapy for cancer treatment

  2024cites this paper
• 基于非靶向代谢组学探索辐射诱导的小鼠肺上皮细胞代谢改变

  2024cites this paper
• A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report

  2024cites this paper
• Interferon-ε loss is elusive 9p21 link to immune-cold tumors, resistant to immune-checkpoint therapy and endogenous CXCL9/10 induction.

  2024cites this paper
• Bimodal accurate H2O2 regulation to equalize tumor-associated macrophage repolarization and immunogenic tumor cell death elicitation

  2024cites this paper
• Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance

  2024cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper